Treatment-refractory autoimmune glial fibrillary acidic protein astrocytopathy: Clinical features, predictive models, therapy
Neurobiology of Disease · 2026-12 · 231 · 107653
DOI: 10.1016/j.nbd.2026.107653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2026-12. Verfasst von Shifeng Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510630, China; Department of Neurology, Institute…. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: A subset of glial fibrillary acidic protein astrocytopathy experiences treatment-refractory disease course, yet the clinical and immunological features defining this subgroup remain incompletely characterized. METHODS: Patients were classified as treatment-refractory (n = 23) or treatment-responsive (n = 30). Clinical, imaging, and outcomes were compared. For subgroup analyses, refractory patients were divided into three groups: no immunoadsorption/plasma exchange (IA/PE) (n = 9), IA/PE monotherapy (n = 4), and IA/PE plus rituximab (n = 10), with functional outcomes compared across groups. Immunoglobulin G (IgG) from refractory patients was applied to a passive transfer mouse model, and single-cell RNA sequencing was performed to explore underlying pathogenic mechanisms. RESULTS: The treatment-refractory group had higher proportion of the meningoencephalomyelitis phenotype (82.6% vs. 53.3%, P = 0.026) and more frequent disturbances of consciousness (65.2% vs. 30.0%, P = 0.011), paraplegia (78.3% vs. 33.3%, P = 0.001), and peripheral nervous system involvement (89.5% vs. 22.2%, P < 0.001). Refractory patients had elevated cerebrospinal fluid glial fibrillary acidic protein and neurofilament light chain levels. Refractory patients more frequently exhibited spinal cord lesions involving three or more segments (65.2% vs. 21.4%, P = 0.002). Disability at last follow-up was greater in the refractory group (median modified Rankin Scale score 3 vs. 1, P < 0.0001). Firth penalized regression model identified peripheral nervous system involvement as the independent predictor of treatment refractoriness (odds ratio = 10.74, P = 0.006). Among refractory patients, the IA/PE-plus-rituximab group had significantly lower long-term mRS scores than the no-IA/PE group (adjusted P = 0.031). GFAPA-IgG from refractory patients induced CD45+ cell infiltration in mouse brain. Single cell analysis demonstrated activation of complement and inflammatory pathways, with astrocytes adopting a pro inflammatory state. CONCLUSION: Treatment refractory disease is marked by severe central and peripheral nervous system injury. Convergent clinical and experimental evidence provides a rationale for B cell targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Geriatrics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510630, China; Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies…
- Department of Geriatrics, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Key Clinical Specialty (Clinical Medicine R…
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
- Department of Pathology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhang, S., Li, H., Yao, H., Li, T., Lai, W., He, S., Lin, P., Yang, J., Shu, Y., Hui, D., Huang, L., Gao, C., Liu, X., & Long, Y. (2026). Treatment-refractory autoimmune glial fibrillary acidic protein astrocytopathy: Clinical features, predictive models, therapy. Neurobiology of Disease, 231, 107653. https://doi.org/10.1016/j.nbd.2026.107653
Vancouver
Zhang S, Li H, Yao H, Li T, Lai W, He S, et al. Treatment-refractory autoimmune glial fibrillary acidic protein astrocytopathy: Clinical features, predictive models, therapy. Neurobiology of Disease. 2026;231:107653. doi:10.1016/j.nbd.2026.107653
BibTeX
@article{Zhang2026,
author = {Zhang, Shifeng and Li, Huilu and Yao, Haiyan and Li, Ting and Lai, Wendong and He, Shiyu and Lin, Peihao and Yang, Jie and Shu, Yaqing and Hui, Dayang and Huang, Li and Gao, Cong and Liu, Xiaorong and Long, Youming},
title = {Treatment-refractory autoimmune glial fibrillary acidic protein astrocytopathy: Clinical features, predictive models, therapy},
journal = {Neurobiology of Disease},
year = {2026},
volume = {231},
pages = {107653},
doi = {10.1016/j.nbd.2026.107653}
}
EUVIMED